Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Prime Medicine Announces Addition of Capabilities to Prime Editing Platform


CAMBRIDGE, Mass., Oct. 19, 2021 /PRNewswire/ -- Prime Medicine, Inc., a company founded to deliver on the promise of Prime Editing, today announced the addition of capabilities to its platform based on recent scientific research.

"We are very excited to see improvements emerging that will further increase Prime Editing's feasibility as a therapeutic approach," said Keith Gottesdiener, MD, CEO of Prime Medicine. "These advancements, on top of an already groundbreaking foundational technology, are likely to increase the efficiency of Prime Editing, and will broaden the areas where Prime Editing might work, potentially extending our reach to additional diseases that no gene editing approach has yet been able to address."

With these new advances made by external scientists, and with Prime Medicine's ongoing efforts by its internal development team, the company expects to further optimize Prime Editing's versatility, precision, and efficiency. Capabilities described in recent papers in Nature Biotechnology and Cell could enable the development of more efficacious therapeutics through improved gene editing activity.

One advance involves an optimized Prime Editing guide RNA (pegRNA). Prime Editing uses a pegRNA molecule to find the gene target and to direct the desired repair or edit. In a paper published in Nature Biotechnology on October 4, 2021, authors led by David R. Liu, one of Prime Medicine's founders, showed that optimized, engineered pegRNAs (epegRNAs) can improve the efficiency of the editing process several-fold. 

The company is also pursuing recently described strategies for improving efficiency by modulating a specific DNA repair pathway. In a paper published in Cell on October 14, 2021, authors led by Liu and Britt Adamson identified a specific DNA repair pathway, called the mismatch repair pathway, that powerfully enhances prime editing efficiency. They showed that editing activity could be increased several-fold, and undesired by-products could be decreased several-fold, by modulating the mismatch repair pathway through several approaches. 

Prime Medicine holds commercial rights from the Broad Institute of MIT and Harvard to use Prime Editing for human therapeutic purposes, while scientists and companies around the world continue to make use of Prime Editing for research purposes and other applications.

About Prime Medicine

Prime Medicine, Inc. is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients and shaping the future of gene editing. For more information, visit www.primemedicine.com or LinkedIn.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact

Morgan Warners
Finsbury Glover Hering
202-295-0124
[email protected]

SOURCE Prime Medicine, Inc.


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: